Expression of FGFR3 and FGFR4 and clinical risk factors associated with progression-free survival in synovial sarcoma

Bridget Charbonneau, Rachel I Vogel, J. Carlos Manivel, Anthony Rizzardi, Stephen C. Schmechel, Simona Ognjanovic, Subree Subramanian, David A Largaespada, Brenda J Weigel

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Although rare, synovial sarcoma (SS) is one of the most common soft tissue sarcomas affecting young adults. To investigate potential tumor markers related to synovial sarcoma prognosis, we carried out a single-institution retrospective analysis of 103 patients diagnosed with SS between 1980 and 2009. Clinical outcome data were obtained from medical records, and archived tissue samples were used to evaluate the relationship between progression-free survival (PFS) and several prognostic factors, including tumor expression of FGFR3 and FGFR4. No associations were found between PFS and gender, body mass index, tumor site, SS18-SSX translocation, or FGFR4 expression. As seen in previous studies, age at diagnosis (<35, 63% versus ≥35 years, 31% 10-year PFS; P =.033), histologic subtype (biphasic, 75% versus monophasic 34% 10-year PFS; P =.034), and tumor size (≤5 cm, 70% versus >5 cm, 22% 10-year PFS; P <.0001) were associated with PFS in SS patients. In addition, in a subset of patients with available archived tumor samples taken prior to chemotherapy or radiation (n = 34), higher FGFR3 expression was associated with improved PFS (P =.030). To the best of our knowledge, this is the largest study of SS to date to suggest a potential clinical role for FGFR3. While small numbers make this investigation somewhat exploratory, the findings merit future investigation on a larger scale.

Original languageEnglish (US)
Pages (from-to)1918-1926
Number of pages9
JournalHuman pathology
Volume44
Issue number9
DOIs
StatePublished - Sep 1 2013

Fingerprint

Synovial Sarcoma
Disease-Free Survival
Neoplasms
Tumor Biomarkers
Sarcoma
Medical Records
Young Adult
Body Mass Index
Radiation
Drug Therapy

Keywords

  • Local recurrence
  • Metastasis
  • Soft tissue sarcoma
  • Tissue microarray

Cite this

Expression of FGFR3 and FGFR4 and clinical risk factors associated with progression-free survival in synovial sarcoma. / Charbonneau, Bridget; Vogel, Rachel I; Manivel, J. Carlos; Rizzardi, Anthony; Schmechel, Stephen C.; Ognjanovic, Simona; Subramanian, Subree; Largaespada, David A; Weigel, Brenda J.

In: Human pathology, Vol. 44, No. 9, 01.09.2013, p. 1918-1926.

Research output: Contribution to journalArticle

Charbonneau, Bridget ; Vogel, Rachel I ; Manivel, J. Carlos ; Rizzardi, Anthony ; Schmechel, Stephen C. ; Ognjanovic, Simona ; Subramanian, Subree ; Largaespada, David A ; Weigel, Brenda J. / Expression of FGFR3 and FGFR4 and clinical risk factors associated with progression-free survival in synovial sarcoma. In: Human pathology. 2013 ; Vol. 44, No. 9. pp. 1918-1926.
@article{705bd75c83b54196a46e17398baec008,
title = "Expression of FGFR3 and FGFR4 and clinical risk factors associated with progression-free survival in synovial sarcoma",
abstract = "Although rare, synovial sarcoma (SS) is one of the most common soft tissue sarcomas affecting young adults. To investigate potential tumor markers related to synovial sarcoma prognosis, we carried out a single-institution retrospective analysis of 103 patients diagnosed with SS between 1980 and 2009. Clinical outcome data were obtained from medical records, and archived tissue samples were used to evaluate the relationship between progression-free survival (PFS) and several prognostic factors, including tumor expression of FGFR3 and FGFR4. No associations were found between PFS and gender, body mass index, tumor site, SS18-SSX translocation, or FGFR4 expression. As seen in previous studies, age at diagnosis (<35, 63{\%} versus ≥35 years, 31{\%} 10-year PFS; P =.033), histologic subtype (biphasic, 75{\%} versus monophasic 34{\%} 10-year PFS; P =.034), and tumor size (≤5 cm, 70{\%} versus >5 cm, 22{\%} 10-year PFS; P <.0001) were associated with PFS in SS patients. In addition, in a subset of patients with available archived tumor samples taken prior to chemotherapy or radiation (n = 34), higher FGFR3 expression was associated with improved PFS (P =.030). To the best of our knowledge, this is the largest study of SS to date to suggest a potential clinical role for FGFR3. While small numbers make this investigation somewhat exploratory, the findings merit future investigation on a larger scale.",
keywords = "Local recurrence, Metastasis, Soft tissue sarcoma, Tissue microarray",
author = "Bridget Charbonneau and Vogel, {Rachel I} and Manivel, {J. Carlos} and Anthony Rizzardi and Schmechel, {Stephen C.} and Simona Ognjanovic and Subree Subramanian and Largaespada, {David A} and Weigel, {Brenda J}",
year = "2013",
month = "9",
day = "1",
doi = "10.1016/j.humpath.2013.03.001",
language = "English (US)",
volume = "44",
pages = "1918--1926",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "9",

}

TY - JOUR

T1 - Expression of FGFR3 and FGFR4 and clinical risk factors associated with progression-free survival in synovial sarcoma

AU - Charbonneau, Bridget

AU - Vogel, Rachel I

AU - Manivel, J. Carlos

AU - Rizzardi, Anthony

AU - Schmechel, Stephen C.

AU - Ognjanovic, Simona

AU - Subramanian, Subree

AU - Largaespada, David A

AU - Weigel, Brenda J

PY - 2013/9/1

Y1 - 2013/9/1

N2 - Although rare, synovial sarcoma (SS) is one of the most common soft tissue sarcomas affecting young adults. To investigate potential tumor markers related to synovial sarcoma prognosis, we carried out a single-institution retrospective analysis of 103 patients diagnosed with SS between 1980 and 2009. Clinical outcome data were obtained from medical records, and archived tissue samples were used to evaluate the relationship between progression-free survival (PFS) and several prognostic factors, including tumor expression of FGFR3 and FGFR4. No associations were found between PFS and gender, body mass index, tumor site, SS18-SSX translocation, or FGFR4 expression. As seen in previous studies, age at diagnosis (<35, 63% versus ≥35 years, 31% 10-year PFS; P =.033), histologic subtype (biphasic, 75% versus monophasic 34% 10-year PFS; P =.034), and tumor size (≤5 cm, 70% versus >5 cm, 22% 10-year PFS; P <.0001) were associated with PFS in SS patients. In addition, in a subset of patients with available archived tumor samples taken prior to chemotherapy or radiation (n = 34), higher FGFR3 expression was associated with improved PFS (P =.030). To the best of our knowledge, this is the largest study of SS to date to suggest a potential clinical role for FGFR3. While small numbers make this investigation somewhat exploratory, the findings merit future investigation on a larger scale.

AB - Although rare, synovial sarcoma (SS) is one of the most common soft tissue sarcomas affecting young adults. To investigate potential tumor markers related to synovial sarcoma prognosis, we carried out a single-institution retrospective analysis of 103 patients diagnosed with SS between 1980 and 2009. Clinical outcome data were obtained from medical records, and archived tissue samples were used to evaluate the relationship between progression-free survival (PFS) and several prognostic factors, including tumor expression of FGFR3 and FGFR4. No associations were found between PFS and gender, body mass index, tumor site, SS18-SSX translocation, or FGFR4 expression. As seen in previous studies, age at diagnosis (<35, 63% versus ≥35 years, 31% 10-year PFS; P =.033), histologic subtype (biphasic, 75% versus monophasic 34% 10-year PFS; P =.034), and tumor size (≤5 cm, 70% versus >5 cm, 22% 10-year PFS; P <.0001) were associated with PFS in SS patients. In addition, in a subset of patients with available archived tumor samples taken prior to chemotherapy or radiation (n = 34), higher FGFR3 expression was associated with improved PFS (P =.030). To the best of our knowledge, this is the largest study of SS to date to suggest a potential clinical role for FGFR3. While small numbers make this investigation somewhat exploratory, the findings merit future investigation on a larger scale.

KW - Local recurrence

KW - Metastasis

KW - Soft tissue sarcoma

KW - Tissue microarray

UR - http://www.scopus.com/inward/record.url?scp=84883446329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883446329&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2013.03.001

DO - 10.1016/j.humpath.2013.03.001

M3 - Article

VL - 44

SP - 1918

EP - 1926

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 9

ER -